Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer

Nicole Williams(The Ohio State University), Robert Wesolowski(The Ohio State University Wexner Medical Center), Darlene M. Bystry(The Ohio State University), Adam Brufsky(University of Pittsburgh), Daniel G. Stover(Harvard University), Michael R. Grever(The Ohio State University Wexner Medical Center), Mara Chambers(University of Kentucky), Dionisia Quiroga(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), William E. Carson(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Sagar Sardesai(The Ohio State University Wexner Medical Center), Mitch A. Phelps(The Ohio State University), Bhuvaneswari Ramaswamy(The Ohio State University), Mathew Cherian(The Ohio State University Wexner Medical Center), Maryam B. Lustberg(Yale Cancer Center), Courtney Johnson(Clinton Foundation), Maria Patterson(The Ohio State University), Saveri Bhattacharya(University of Pennsylvania), Kasey Hill(The Ohio State University), Julie Stephens(The Ohio State University), Min Chen(Nanjing University of Chinese Medicine), Anne M. Noonan(The Ohio State University)
Therapeutic Advances in Medical Oncology
January 1, 2023
Cited by 14


Related Papers